HSBC Holdings’s Fulcrum Therapeutics FULC Stock Holding History

HSBC Holdings’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$426K	Buy	109,353 +50,717	+86%	+$309K	﹤0.01%	2357
2026 Q1	$442K	Buy	58,636 +15,374	+36%	+$143K	﹤0.01%	2279
2025 Q4	$498K	Sell	43,262 -10,544	-20%	-$107K	﹤0.01%	2316
2025 Q3	$474K	Buy	53,806 +4,270	+9%	+$30.9K	﹤0.01%	2133
2025 Q2	$357K	Sell	49,536 -25,425	-34%	-$136K	﹤0.01%	2336
2025 Q1	$219K	Sell	74,961 -998	-1%	-$3.67K	﹤0.01%	2577
2024 Q4	$355K	Buy	75,959 +26,944	+55%	+$99.4K	﹤0.01%	2391
2024 Q3	$178K	Buy	+49,015	New	+$364K	﹤0.01%	2659
2024 Q2	–	Sell	-149,627	Closed	-$1.41M	–	3018
2024 Q1	$1.41M	Buy	+149,627	New	+$1.34M	﹤0.01%	1635

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HSBC Holdings's FULC Position: Q2 2026 in Review

HSBC Holdings increased its Fulcrum Therapeutics (FULC) stake by 86% in Q2 2026, buying an estimated $309K and bringing the position to 109,353 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #2357.

HSBC Holdings first reported a position in FULC in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.41M in Q1 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

HSBC Holdings held 109,353 shares of Fulcrum Therapeutics worth $426K as of Q2 2026.
HSBC Holdings bought 50,717 Fulcrum Therapeutics shares in Q2 2026, an estimated $309K.
Fulcrum Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2357 holding.
HSBC Holdings first reported a position in Fulcrum Therapeutics in Q1 2024 and has held it in 9 quarters since.
HSBC Holdings's Fulcrum Therapeutics position peaked at $1.41M in Q1 2024.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.